[go: up one dir, main page]

ES2055845T3 - Composicion farmaceutica para el tratamiento de la osteoporosis. - Google Patents

Composicion farmaceutica para el tratamiento de la osteoporosis.

Info

Publication number
ES2055845T3
ES2055845T3 ES90120567T ES90120567T ES2055845T3 ES 2055845 T3 ES2055845 T3 ES 2055845T3 ES 90120567 T ES90120567 T ES 90120567T ES 90120567 T ES90120567 T ES 90120567T ES 2055845 T3 ES2055845 T3 ES 2055845T3
Authority
ES
Spain
Prior art keywords
treatment
pharmaceutical composition
osteoporosis
estrogen
thyroid hormone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90120567T
Other languages
English (en)
Inventor
Tomoshi Nippon Zoki Phar Miura
Shinichiro Nippon Zoki Aonuma
Hiroyuki Nippon Zoki Pha Ohara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2055845T3 publication Critical patent/ES2055845T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN COMPUESTO FARMACEUTICO PARA EL TRATAMIENTO DE OSTEOPOROSIS, COMPRENDE UN ESTREGENO Y UNA HORMONA DE TIROIDE COMO INGREDIENTES EFECTIVOS. UTILIZANDO EL ESTROGENO CON COMBINACION CON LA HORMONA DE TIROIDE, SE PUEDE OBTENER UNA ACTIVIDAD MUCHISIMO MAS GRANDE EN INCREMENTAR LA CANTIDAD DE HUESO QUE EN EL CASO DE SUMINISTRAR SOLAMENTE EL ESTROGENO.
ES90120567T 1989-10-26 1990-10-26 Composicion farmaceutica para el tratamiento de la osteoporosis. Expired - Lifetime ES2055845T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP28114189 1989-10-26

Publications (1)

Publication Number Publication Date
ES2055845T3 true ES2055845T3 (es) 1994-09-01

Family

ID=17634937

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90120567T Expired - Lifetime ES2055845T3 (es) 1989-10-26 1990-10-26 Composicion farmaceutica para el tratamiento de la osteoporosis.

Country Status (6)

Country Link
US (1) US5116828A (es)
EP (1) EP0424954B1 (es)
JP (1) JP3113269B2 (es)
AT (1) ATE104854T1 (es)
DE (1) DE69008476T2 (es)
ES (1) ES2055845T3 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2131822C (en) * 1992-03-21 2002-12-17 Walter Elger Use of estriol for treating climacteric osteoporosis
DK0676951T3 (da) * 1992-12-29 2002-06-03 Michael F Holick Anvendelse af vitamin-D-glycosider til behandling eller forebyggelse af osteoporose
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
ES2227523T3 (es) * 1993-01-19 2005-04-01 Endorecherche Inc. Usos terapeuticos y sistemas de suministro de deshidroepiandrosterona.
US20030170290A1 (en) * 1993-06-16 2003-09-11 Shug Austin L. Delayed release carnitine
JPH09100293A (ja) * 1995-10-03 1997-04-15 Kanebo Ltd インターロイキン８の作用増強剤
DE69636677D1 (de) 1995-12-13 2006-12-14 Univ California Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors
US6266622B1 (en) * 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US6197291B1 (en) 1996-06-27 2001-03-06 Kanebo Limited Agent for potentiating the effect of interleukin-8
IT1292129B1 (it) * 1997-06-11 1999-01-25 Sunnimex Ltd Medicamento utile per ridurre la massa grassa ed aumentare la massa magra nella donna in menopausa ed in entrambi i sessi nella
US6117429A (en) * 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US6342611B1 (en) * 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
EP1083904A2 (en) * 1998-06-11 2001-03-21 Endorecherche Inc. Pharmaceutical compositions and uses for androst-5-ene-3 beta,17 beta-diol
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
JP2007512359A (ja) * 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
AU2006249350B2 (en) 2003-11-19 2012-02-16 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
DE102004025985A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estriol- und Estetrol-Prodrugs
US20050277625A1 (en) * 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
US7534780B2 (en) * 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
CA2606498C (en) * 2005-05-26 2016-08-09 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
MX2008000412A (es) * 2005-07-12 2008-03-10 Warner Chilcott Co Inc Profarmacos de 3-ester de estradiol.
CN101218245B (zh) * 2005-07-12 2011-08-17 沃纳奇尔科特有限责任公司 炔雌醇的3-酯前药
CA2624788C (en) 2005-10-12 2011-04-19 Unimed Pharmaceuticals, Llc Improved testosterone gel and method of use
US20070123500A1 (en) * 2005-11-29 2007-05-31 Gerd Mueller Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
US20070197488A1 (en) * 2005-11-29 2007-08-23 Olaf Peters Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
US20070135375A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Sulfamoyl sulfonate prodrugs
US8288366B2 (en) * 2006-06-20 2012-10-16 Chochinov Ronald H Formulation for hair growth
AU2008311698C1 (en) 2007-10-11 2014-03-06 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein Siglec-15
JP2012520883A (ja) * 2009-03-16 2012-09-10 アイピントゥル，エルエルシー アルツハイマー病及び骨粗鬆症の治療並びに老化の軽減
AU2017363206A1 (en) 2016-11-21 2019-06-13 Viking Therapeutics, Inc. Method of treating glycogen storage disease
JP7168660B2 (ja) 2017-06-05 2022-11-09 バイキング・セラピューティクス・インコーポレイテッド 線維症の処置のための組成物
AU2019238090B2 (en) 2018-03-22 2024-08-01 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6434M (es) * 1967-02-23 1968-11-04
US4041022A (en) * 1967-05-24 1977-08-09 Ciba-Geigy Corporation Process for the manufacture of thyrocalcitonin
GB2138286B (en) * 1983-04-19 1986-10-08 Dr Christopher Harry Mortimer Pharmaceutical composition for the treatment of hair loss
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
JPS6089422A (ja) * 1983-10-24 1985-05-20 Kureha Chem Ind Co Ltd 抗骨粗鬆症剤
US4812304A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Treatment of osteoporosis
US4822609A (en) * 1984-12-21 1989-04-18 The Procter & Gamble Company Treatment of osteoporosis
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
US5001118A (en) * 1986-12-29 1991-03-19 Kureha Kagaku Kogyo Kabushiki Kaisha Method for preventing senescence and increasing bone mass
JP2542846B2 (ja) * 1987-05-22 1996-10-09 日本臓器製薬株式会社 糖尿病治療剤
US4946679A (en) * 1988-07-25 1990-08-07 Thys Jacobs Susan Method for the treatment of premenstrual syndrome
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome

Also Published As

Publication number Publication date
DE69008476D1 (de) 1994-06-01
US5116828A (en) 1992-05-26
DE69008476T2 (de) 1994-09-01
EP0424954B1 (en) 1994-04-27
JP3113269B2 (ja) 2000-11-27
EP0424954A1 (en) 1991-05-02
JPH03209328A (ja) 1991-09-12
ATE104854T1 (de) 1994-05-15

Similar Documents

Publication Publication Date Title
ES2055845T3 (es) Composicion farmaceutica para el tratamiento de la osteoporosis.
CY1110287T1 (el) Χρηση της ανθρωπινης παραθυρεοειδους ορμονης
ATE79271T1 (de) Pharmazeutische zubereitung zur anwendung fuer die anreicherung von knochenmasse.
GR3002487T3 (en) Medicament with anti-tumoral action containing hexadecylphosphocholine
BR9402902A (pt) Hormônio paratiróideo e raloxifeno, compostos e formulação farmacêutica.
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
FI903213A0 (fi) Foer transdermal administration avsett gestoden innehaollande medel.
BR8801242A (pt) Processo de preparar uma composicao para fornecer uma quantidade efetiva de uma dose constante de um ingrediente ativo a um animal e a respectiva composicao
ES2031096T3 (es) Una composicion de implante mejorada a base de estradiol y metodo para su preparacion.
BR9403783A (pt) Uso de uma composição cosmética
GR3019514T3 (en) Pharmaceutical preparation for the treatment of prolonged coagulation time
ATE220321T1 (de) Feste flupirtin enthaltende orale darreichungsformen mit kontrollierter wirkstoffabgabe
ZA882151B (en) Binding inducing compositions
DK0613368T3 (da) Hudregenererende kosmetisk sammensætning
MX170055B (es) , "composicion insecticida y procedimiento para su obtencion
ATE311897T1 (de) Behandlung von multiplersklerose mit einer kombination von interferon und wachstumshormone
ES2059403T3 (es) Composicion util en el tratamiento de deficiencias de estrogenos.
ES2085199B1 (es) Un procedimiento para la preparacion de una formulacion depot.
GR3001277T3 (en) Chlorpheniramine therapy
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto
KR970705397A (ko) 골다공증 치료를 위한 에스트로젠 화합물 및 부갑상선 호르몬(estrogens and parathyroid hormone for treating osteoporosis)
EP0348664A3 (en) Pharmaceutical compositions containing monoacetoacetins for treating tumours
AR241632A1 (es) Procedimiento para preparar una composicion farmaceutica liquida de una 4-aroilimidazol-2-ona.
IT1239478B (it) Sale dell'idrocortisone emisuccinato con la clorexidina per l'impiego topico e composizioni farmaceutiche che lo contengono
JPS52130926A (en) Medicinal composition comprising pentazocine and salicylamide

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 424954

Country of ref document: ES